Completed PHASE2 INTERVENTIONAL 2-arm NCT00741988

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer

Sponsor: Bristol-Myers Squibb

Conditions Non-Small Cell Lung Cancer

Interventions Bevacizumab Carboplatin Ixabepilone

Updated 6 times since 2017 Last updated: Dec 13, 2021 Started: Sep 30, 2008 Primary completion: Sep 30, 2010 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Genentech, Inc.
SCRI Development Innovations, LLC

Data source: SCRI Development Innovations, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bethesda, United States , Cincinnati, United States , Columbia, United States , Fort Myers, United States , Gainesville, United States , Grand Rapids, United States , Great Falls, United States , Kansas City, United States , Louisville, United States , Nashville, United States and 3 more locations